logo
McCauley Propeller secures ANAC certification for Beechcraft King Air B300 series high-performance propeller

McCauley Propeller secures ANAC certification for Beechcraft King Air B300 series high-performance propeller

Business Wire22-04-2025
WICHITA, Kan.--(BUSINESS WIRE)-- McCauley Propeller Systems announced today its newest C780 propeller for the Beechcraft King Air B300 series, featuring four aluminum swept blades and a 105-inch diameter, has successfully achieved certification from the National Civil Aviation Agency of Brazil (ANAC). Brazil is the second largest installed base globally for Beechcraft King Air turboprops.
McCauley Propeller Systems is a division of Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company.
"The high-performance McCauley C780 propeller, with its lightweight scimitar blade design, will improve the flying experience for over 700 King Airs in Brazil," said Jason Hull, vice president and general manager, McCauley Propeller Systems. 'The propeller offers versatility and performance enhancements to equip customers in the region with smart solutions for their unique missions and circumstances.'
With the new C780 propeller, King Air B300 owners and operators experience:
Propeller weight savings of more than 50 pounds compared to previous options
Increased takeoff and climb performance
Reduced noise in the cabin and cockpit
Extended Time Between Overhaul (TBO) of 5,000 hours or 72 months
Textron Aviation's 5,000 hours or 36-month limited propeller warranty
King Air B300 customers can have the propeller installed on their aircraft at a Textron Aviation Service Center or Authorized McCauley Service Facility without any additional modifications required.
For more information, visit mccauley.txtav.com/featured-products.
About McCauley Propeller Systems
McCauley is one of the world's largest full-line propeller manufacturers, with more than 500 models available. With more than 85 years of design and manufacturing experience, McCauley continues to be a pioneer in the general aviation industry. Historically, our propellers are FAA certified as original equipment for aircraft built by Textron Aviation, British Aerospace, Fairchild, Grumman, Jetstream, Piper, Stoddard Hamilton and many others. Our product lines have always served a wide range of markets: commercial, military, agricultural and commuter airlines, as well as personal and business aviation. McCauley propellers are in the field on more than 350,000 aircraft around the world - a testimony to our continuing commitment to excellence. For more information, visit www.mccauley.txtav.com.
About Textron Aviation
We inspire the journey of flight. For more than 95 years, Textron Aviation Inc., a Textron Inc. company, has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops, and high-performance pistons, to special mission, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable and flexible flight.
For more information, visit www.txtav.com | www.defense.txtav.com | www.scorpionjet.com.
About Textron Inc.
Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, Arctic Cat, Textron Systems, and TRU Simulation + Training. For more information, visit: www.textron.com.
Certain statements in this press release are forward-looking statements which may project revenues or describe strategies, goals, outlook or other non-historical matters; these statements speak only as of the date on which they are made, and we undertake no obligation to update or revise any forward-looking statements. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)

Yahoo

time18 minutes ago

  • Yahoo

RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)

Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio

Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT

Yahoo

time18 minutes ago

  • Yahoo

Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT

AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. Global net revenues for the quarter for the Immunology portfolio rose to $6.264 billion, reflecting a growth of 16.6% on a reported basis or 18.1% on an operational basis. AbbVie Inc. (NYSE:ABBV) also experienced growth in global net revenues in the Neuroscience portfolio to $2.282 billion, reflecting a 16.1% increase on a reported basis or 17% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

VAALCO Schedules Second Quarter 2025 Earnings Release and Conference Call
VAALCO Schedules Second Quarter 2025 Earnings Release and Conference Call

Yahoo

time18 minutes ago

  • Yahoo

VAALCO Schedules Second Quarter 2025 Earnings Release and Conference Call

HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY; LSE: EGY) ('Vaalco' or the 'Company') today announced the timing of its second quarter 2025 earnings release and conference call. The Company will issue its second quarter 2025 earnings release on Thursday, August 7, 2025 after the close of trading on the New York Stock Exchange and host a conference call to discuss its financial and operational results on Friday morning, August 8, 2025 at 9:00 a.m. Central Time (10:00 a.m. Eastern Time and 3:00 p.m. London Time.) Interested parties in the United States may participate toll-free by dialing (833) 685-0907. Interested parties in the United Kingdom may participate toll-free by dialing 08082389064. Other international parties may dial (412) 317-5741. Participants should ask to be joined to the 'Vaalco Energy Earnings Conference Call.' This call will also be webcast on VAALCO's website at An audio replay will be available on the Company's website following the call. About Vaalco Vaalco, founded in 1985 and incorporated under the laws of Delaware, is a Houston, Texas, USA based, independent energy company with a diverse portfolio of production, development and exploration assets across Gabon, Egypt, Côte d'Ivoire, Equatorial Guinea, Nigeria and Canada. For Further Information Vaalco Energy, Inc. (General and Investor Enquiries) +00 1 713 543 3422 Website: Al Petrie Advisors (US Investor Relations) +00 1 713 543 3422 Al Petrie / Chris Delange Buchanan (UK Financial PR) +44 (0) 207 466 5000 Ben Romney / Barry Archer Vaalco@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store